产品
编 号：F748120
产品类型
规格
价格
是否有货
结构图
CAS No: 1964506-31-7
产品详情
生物活性：
ODN 21158 is a potent G-modified TLR3 and TLR9 inhibitor. ODN 21158 shows no cytotoxic. ODN 21158 inhibits IFN-α secretion in a dose dependent manner.
体外研究：
ODN 21158 (0.01, 0.1, 1, 10 μM) shows no cytotoxic in human PBMCs.ODN 21158 (0.01, 0.1, 1, 10 μM; 24 h) inhibits IFN-α secretion in a dose dependent manner when stimulated with CpG-ODN 2216 (3 μM) in Human PBMCs.ODN 21158 (0.01, 0.1, 1, 10 μM; 48 h) stimulated with CpG-ODN 2006 (100 nM) failes to inhibit IL-6 release of PBMCs.ODN 21158 (0.01, 0.1, 1, 10 μM; 48 h) inhibits the release of IL-6 when stimulated with imiquimod (5 μg/ml) in human PBMCs.ODN 21158 (0.1, 1, 10 μM; 24 h) inhibits the release of IL-6 in B-cells when stimulated with imiquimod (5 μg/ml) and CpG-ODN 2006 (100 nM).
ODN 21158 is a potent G-modified TLR3 and TLR9 inhibitor. ODN 21158 shows no cytotoxic. ODN 21158 inhibits IFN-α secretion in a dose dependent manner.
体外研究：
ODN 21158 (0.01, 0.1, 1, 10 μM) shows no cytotoxic in human PBMCs.ODN 21158 (0.01, 0.1, 1, 10 μM; 24 h) inhibits IFN-α secretion in a dose dependent manner when stimulated with CpG-ODN 2216 (3 μM) in Human PBMCs.ODN 21158 (0.01, 0.1, 1, 10 μM; 48 h) stimulated with CpG-ODN 2006 (100 nM) failes to inhibit IL-6 release of PBMCs.ODN 21158 (0.01, 0.1, 1, 10 μM; 48 h) inhibits the release of IL-6 when stimulated with imiquimod (5 μg/ml) in human PBMCs.ODN 21158 (0.1, 1, 10 μM; 24 h) inhibits the release of IL-6 in B-cells when stimulated with imiquimod (5 μg/ml) and CpG-ODN 2006 (100 nM).
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备